{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:20:49Z","timestamp":1790256049308,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s11096-019-00860-0","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T13:24:11Z","timestamp":1561469051000},"page":"981-992","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Improving medication safety in oncology care: impact of clinical pharmacy interventions on optimizing patient safety"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7240-6857","authenticated-orcid":false,"given":"Himanshu","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthasarathi","family":"Gurumurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,25]]},"reference":[{"issue":"12","key":"860_CR1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1200\/JCO.2016.71.5292","volume":"35","author":"HJ Burstein","year":"2017","unstructured":"Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, et al. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017;35(12):1341\u201367.","journal-title":"J Clin Oncol"},{"issue":"4","key":"860_CR2","first-page":"25","volume":"8","author":"N Utku","year":"2011","unstructured":"Utku N. New approaches to treat cancer-what they can and cannot do. Biotechnol Healthc. 2011;8(4):25.","journal-title":"Biotechnol Healthc"},{"issue":"1","key":"860_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s002280050331","volume":"53","author":"M Lapeyre-Mestre","year":"1997","unstructured":"Lapeyre-Mestre M, Gary J, Machelard-Roumagnac M, Bonhomme C, Bugat R, Montastruc JL. Incidence and cost of adverse drug reactions in a French cancer institute. Eur J Clin Pharmacol. 1997;53(1):19\u201322.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"860_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1634\/theoncologist.2016-0301","volume":"22","author":"J Peppercorn","year":"2017","unstructured":"Peppercorn J. Financial toxicity and societal costs of cancer care: distinct problems require distinct solutions. Oncologist. 2017;22(2):123\u20135.","journal-title":"Oncologist"},{"issue":"2","key":"860_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2478\/raon-2014-0050","volume":"49","author":"RR Kukec","year":"2015","unstructured":"Kukec RR, Grabnar I, Vovk T, Mrhar A, Kovac V, Cufer T. Febrile neutropenia in chemotherapy treated small-cell lung cancer patients. Radiol Oncol. 2015;49(2):173\u201380.","journal-title":"Radiol Oncol"},{"issue":"9","key":"860_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40264-016-0432-y","volume":"39","author":"M Mann","year":"2016","unstructured":"Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, et al. Active surveillance versus spontaneous reporting for first-line antiretroviral medicines in Namibia: a cost-utility analysis. Drug Saf. 2016;39(9):859\u201372.","journal-title":"Drug Saf"},{"issue":"1","key":"860_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4103\/0971-5851.177015","volume":"37","author":"D Chopra","year":"2016","unstructured":"Chopra D, Rehan HS, Sharma V, Mishra R. Chemotherapy-induced adverse drug reactions in oncology patients: a prospective observational survey. Indian J Med Paediatr Oncol. 2016;37(1):42.","journal-title":"Indian J Med Paediatr Oncol"},{"key":"860_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/DHPS.S116924","volume":"8","author":"SA Belachew","year":"2016","unstructured":"Belachew SA, Erku DA, Mekuria AB, Gebresillassie BM. Pattern of chemotherapy-related adverse effects among adult cancer patients treated at Gondar University Referral Hospital, Ethiopia: a cross-sectional study. Drug Healthc Patient Saf. 2016;8:83.","journal-title":"Drug Healthc Patient Saf"},{"key":"860_CR9","doi-asserted-by":"publisher","first-page":"960","DOI":"10.2146\/ajhp130278","volume":"71","author":"SF Wong","year":"2014","unstructured":"Wong SF, Bounthavong M, Nguyen C, Bechtoldt K, Hernandez E. Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic. Am J Health Syst Pharm. 2014;71:960\u20135.","journal-title":"Am J Health Syst Pharm"},{"key":"860_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s11096-014-9915-z","volume":"36","author":"F Caracuel","year":"2014","unstructured":"Caracuel F, Banos U, Herrera MD, Ramirez G, Munoz N. Influence of pharmaceutical care on the delayed emesis associated with chemotherapy. Int J Clin Pharm. 2014;36:287\u201390.","journal-title":"Int J Clin Pharm"},{"issue":"7 Suppl 3","key":"860_CR11","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.2146\/ajhp100078","volume":"67","author":"LB Michaud","year":"2010","unstructured":"Michaud LB. Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer. Am J Health Syst Pharm. 2010;67(7 Suppl 3):S20\u201330.","journal-title":"Am J Health Syst Pharm"},{"key":"860_CR12","doi-asserted-by":"crossref","unstructured":"Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. In: Mayo clinic proceedings, vol. 87, no. 10. Elsevier; 2012. p. 935\u201343.","DOI":"10.1016\/j.mayocp.2012.07.007"},{"issue":"2","key":"860_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4103\/2229-3485.154014","volume":"6","author":"A Sharma","year":"2015","unstructured":"Sharma A, Kumari KM, Manohar HD, Bairy KL, Thomas J. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care hospital in South India. Perspect Clin Res. 2015;6(2):109.","journal-title":"Perspect Clin Res"},{"issue":"2","key":"860_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jsps.2013.02.003","volume":"22","author":"MJ Alomar","year":"2014","unstructured":"Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014;22(2):83\u201394.","journal-title":"Saudi Pharm J"},{"key":"860_CR15","unstructured":"US Department of Health and Human Services. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. US Department of Health and Human Services. National Institutes of Health. National Cancer Institute. 2009."},{"key":"860_CR16","unstructured":"The use of the WHO\u2013UMC system for standardised case causality assessment. \n                    http:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/WHOcausality_assessment.pdf\n                    \n                  . Accessed 6 Aug 2017."},{"issue":"2","key":"860_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"860_CR18","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1093\/ajhp\/49.9.2229","volume":"49","author":"SC Hartwig","year":"1992","unstructured":"Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Health Syst Pharm. 1992;49(9):2229\u201332.","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"860_CR19","first-page":"538","volume":"27","author":"GT Schumock","year":"1992","unstructured":"Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27(6):538.","journal-title":"Hosp Pharm"},{"key":"860_CR20","first-page":"107815521773968","volume":"1","author":"H Patel","year":"2017","unstructured":"Patel H, Gurumurthy P. Implementation of clinical pharmacy services in an academic oncology practice in India. J Oncol Pharm Pract. 2017;1:1078155217739684.","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"860_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ejca.2004.09.026","volume":"41","author":"K Jordan","year":"2005","unstructured":"Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer. 2005;41(2):199\u2013205.","journal-title":"Eur J Cancer"},{"issue":"9","key":"860_CR22","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1634\/theoncologist.12-9-1143","volume":"12","author":"K Jordan","year":"2007","unstructured":"Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist. 2007;12(9):1143\u201350.","journal-title":"Oncologist"},{"issue":"suppl 5","key":"860_CR23","doi-asserted-by":"publisher","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","volume":"21","author":"F Roila","year":"2010","unstructured":"Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(suppl 5):v232\u201343.","journal-title":"Ann Oncol"},{"key":"860_CR24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.34.7_suppl.220","author":"S Toutounji","year":"2016","unstructured":"Toutounji S, Fung R, Enright K. Improving anti-emetics in chemotherapy induced nausea and vomiting. ASCO. 2016. \n                    https:\/\/doi.org\/10.1200\/jco.2016.34.7_suppl.220\n                    \n                  .","journal-title":"ASCO"},{"issue":"2","key":"860_CR25","doi-asserted-by":"publisher","first-page":"188","DOI":"10.4103\/IJPC.IJPC_153_16","volume":"23","author":"VT LeBaron","year":"2017","unstructured":"LeBaron VT, Palat G, Sinha S, Chinta SK, Jamima BJ, Pilla UL, et al. Recommendations to support nurses and improve the delivery of oncology and palliative care in India. Indian J Palliat Care. 2017;23(2):188\u201398.","journal-title":"Indian J Palliat Care"},{"key":"860_CR26","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.7314\/APJCP.2015.16.5.1699","volume":"16","author":"A Ulas","year":"2015","unstructured":"Ulas A, Silay K, Akinci S, Dede DS, Akinci MB, Sendur MA, et al. Medication errors in chemotherapy preparation and administration: a survey conducted among oncology nurses in Turkey. Asian Pac J Cancer Prev. 2015;16:1699\u2013705.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6","key":"860_CR27","doi-asserted-by":"publisher","first-page":"687","DOI":"10.4103\/0250-474X.174990","volume":"77","author":"VK Saini","year":"2015","unstructured":"Saini VK, Sewal RK, Ahmad Y, Medhi B. Prospective observational study of adverse drug reactions of anticancer drugs used in cancer treatment in a tertiary care hospital. Indian J Pharm Sci. 2015;77(6):687.","journal-title":"Indian J Pharm Sci"},{"key":"860_CR28","first-page":"1209","volume":"5","author":"MK Vijayalaxmi","year":"2011","unstructured":"Vijayalaxmi MK, Palatty PL, Bhat P, Dinesh M. A comparative assessment of the ADR profile in various anti-cancer regimens excluding gastro-intestinal and haematological toxicity at a tertiary care centre. J Clin Diagn Res. 2011;5:1209\u201313.","journal-title":"J Clin Diagn Res"},{"issue":"9","key":"860_CR29","first-page":"626","volume":"12","author":"PM Lau","year":"2004","unstructured":"Lau PM, Stewart K, Dooley M. The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer. 2004;12(9):626\u201333.","journal-title":"Support Care Cancer"},{"key":"860_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1191\/1078155205jp149oa","volume":"1","author":"HS Sano","year":"2005","unstructured":"Sano HS, Waddell JA, Solimando DA Jr, Doulaveris P, Myhand R. Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost. J Oncol Pharm Pract. 2005;1:21\u201330.","journal-title":"J Oncol Pharm Pract"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-019-00860-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-019-00860-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-019-00860-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T23:23:20Z","timestamp":1592954600000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-019-00860-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,25]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["860"],"URL":"https:\/\/doi.org\/10.1007\/s11096-019-00860-0","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,25]]},"assertion":[{"value":"16 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}